BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6459763)

  • 1. In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic.
    Snepar R; Poporad G; Romano J; Levison ME
    Antimicrob Agents Chemother; 1981 Nov; 20(5):642-7. PubMed ID: 6459763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antibacterial activity of moxalactam, an oxa-beta-lactam antibiotic.
    Goto S
    Rev Infect Dis; 1982; 4 Suppl():S501-10. PubMed ID: 6218559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drug evaluations: moxalactam (Moxam, Eli Lilly).
    Polk RE
    Drug Intell Clin Pharm; 1982 Feb; 16(2):104-12. PubMed ID: 6210519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
    Fitzpatrick BJ; Standiford HC
    Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vitro activity of moxalactam against 430 clinical, bacterial isolates.
    Digranes A; Benonisen E; Dibb WL; Ostervold B
    Acta Pathol Microbiol Immunol Scand B; 1982 Feb; 90(1):69-72. PubMed ID: 6211028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.
    Yoshida T; Matsuura S; Mayama M; Kameda Y; Kuwahara S
    Antimicrob Agents Chemother; 1980 Mar; 17(3):302-12. PubMed ID: 6448572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of moxalactam.
    Reed MD; Bertino JS; Aronoff SC; Speck WT; Blumer JL
    Clin Pharm; 1982; 1(2):124-34. PubMed ID: 6224626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of moxalactam against anaerobic bacteria.
    Gilchrist MJ; Washington JA
    Rev Infect Dis; 1982; 4 Suppl():S511-5. PubMed ID: 6218560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of the novel oxa-beta-lactam antibiotic moxalactam (LY 127935) against dense populations of selected Gram-negative bacilli.
    Greenwood D; Eley A; Pearson N; O'Grady F
    J Antimicrob Chemother; 1981 Apr; 7(4):353-62. PubMed ID: 6265424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro studies of moxalactam (LY127935), a new beta-lactam antibiotic with significant activity against gram-negative bacteria.
    DeMaria A; Alvarez S; Klein JO; McCabe WR
    Infection; 1980; 8 Suppl 3():S 261-7. PubMed ID: 6447671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity and beta-lactamase stability of moxalactam and other selected cephalosporin antibiotics.
    Vuye A
    Arzneimittelforschung; 1981; 31(8):1290-5. PubMed ID: 6457607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.
    Reimer LG; Mirrett S; Reller LB
    Antimicrob Agents Chemother; 1980 Mar; 17(3):412-6. PubMed ID: 6448577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxalactam therapy for bacterial infections.
    Winston DJ; Busuttil RW; Kurtz TO; Young LS
    Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
    Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
    Eickhoff TC; Ehret J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):435-42. PubMed ID: 6264845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Baumgärtner M; Dickgiesser N; Müller S; Wundt W
    Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.